ID: ALA435834

Max Phase: Preclinical

Molecular Formula: C14H20N2O10

Molecular Weight: 376.32

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=c1ccn([C@@H]2O[C@H](CO[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1

Standard InChI:  InChI=1S/C14H20N2O10/c17-3-5-8(19)11(22)13(26-5)24-4-6-9(20)10(21)12(25-6)16-2-1-7(18)15-14(16)23/h1-2,5-6,8-13,17,19-22H,3-4H2,(H,15,18,23)/t5-,6-,8-,9-,10-,11-,12-,13-/m1/s1

Standard InChI Key:  FPFICLNIIWPFTA-JXHPLLHESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 376.32

Molecular Weight (Monoisotopic): 376.1118

AlogP: -4.39

#Rotatable Bonds: 5

Polar Surface Area: 183.70

Molecular Species: NEUTRAL

HBA: 11

HBD: 6

#RO5 Violations: 2

HBA (Lipinski): 12

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 9.70

CX Basic pKa:

CX LogP: -3.56

CX LogD: -3.56

Aromatic Rings: 1

Heavy Atoms: 26

QED Weighted: 0.29

Np Likeness Score: 1.71

References

1. Dini C, Drochon N, Feteanu S, Guillot JC, Peixoto C, Aszodi J..  (2001)  Synthesis of analogues of the O-beta-D-ribofuranosyl nucleoside moiety of liposidomycins. Part 1: contribution of the amino group and the uracil moiety upon the inhibition of MraY.,  11  (4): [PMID:11229763] [10.1016/s0960-894x(00)00715-0]

2. Patel B, Ryan P, Makwana V, Zunk M, Rudrawar S, Grant G..  (2019)  Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.,  171  [PMID:30933853] [10.1016/j.ejmech.2019.01.071]

Source

Source(1):

• Scientific Literature